Nis Register Study Comparing Seroquel and Seroquel Prolong

Condition(s) targeted: Comparing Hospitalisation Time With Seroquel and Seroquel Prolong

Phase: N/A

Status: Recruiting

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Yrjö Ovaskainen, Study Director, Affiliation: Medical Affairs Manager, MD, psychiatrist
Kari Hänninen, Principal Investigator, Affiliation: MD, psychiatrist

Overall contact:
AstraZeneca Finland Clinical Study Information, Phone: +358 10 23 010

The general aim of this non interventional study is to clarify what are the current clinical treatment practices of Quetiapine Immediate Release and Quetiapine Extended Release. The primary objectives of the study are: 1. To collect information on the used Quetiapine Immediate Release or Quetiapine Extended Release medication 2. To collect information on duration and number of hospitalisation days 3. Change of GAF points

Official title: A Local Non Interventional Retrospective Register Study of the Current Clinical Treatment Practices and the Number of Hospitalization Days With Seroquel or Seroquel Prolong.

Study design: Observational Model: Case Control, Time Perspective: Retrospective

Primary outcome:

Hospitalisation time

Treatment practice

Secondary outcome:

Primary diagnosis

Medication at the end of hospitalisation

GAF rating points

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Medication: Seroquel or Seroquel Prolong

- Diagnosis: F20-F29 or F30-F31 (ICD-10)

- In-patient

Exclusion Criteria:

- None

AstraZeneca Finland Clinical Study Information, Phone: +358 10 23 010

Research Site, Lappeenranta, Finland; Recruiting

Starting date: August 2009
Last updated: June 23, 2010